Silvia Marchesi - Publications

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Journal: Thyroid : official journal of the American Thyroid Association

Published: June 24, 2026

Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.

Journal: Tumori

Published: June 04, 2026

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.

Journal: Cancer cell international

Published: November 06, 2025

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.

Journal: The oncologist

Published: October 07, 2025

A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: September 13, 2025

FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: May 14, 2025

Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.

Journal: NPJ precision oncology

Published: April 14, 2025

First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma.

Journal: Therapeutic advances in medical oncology

Published: February 22, 2025

Comparing survival and outcomes in isolated versus polytrauma-associated TBI: a retrospective cohort study.

Journal: Journal of neurosurgical sciences

Published: December 17, 2024

Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives.

Journal: Molecular diagnosis & therapy

Published: October 28, 2024

Erratum to "Unleashing precision: A review of targeted approaches in pleural mesothelioma" [Crit. Rev. Oncol./Hematol. 203C (2024) 104481].

Journal: Critical reviews in oncology/hematology

Published: September 24, 2024

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Oncology

Published: August 28, 2024